The molecular biology of prostate cancer: current understanding and clinical implications
- 27 December 2017
- journal article
- review article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 21 (1) , 22-36
Abstract
With continuous progress over the past few decades in understanding diagnosis, treatment, and genetics, much has been learned about the prostate cancer-diagnosed genome. A comprehensive MEDLINE® and Google scholar literature search was conducted using keyword variations relating to the genetics of prostate cancer such as chromosomal alterations, androgen receptor, castration-resistant, inheritance, polymorphisms, oncogenes, metastasis, biomarkers, and immunotherapy. Traditionally, androgen receptors (AR) have been the focus of research. Recently, identification of recurrent chromosomal alterations that lead to either multiplication of regions (gain-of-function) or deletion of regions (loss-of-function) has opened the door to greater genetic accessibility. These chromosomal aberrations lead to variation in copy number and gene expression. Some of these chromosomal alterations are inherited, while others undergo somatic mutations during disease progression. Inherited gene mutations that make one susceptible to prostate cancer have been identified with familial-linked studies. Somatic genes that progress tumorigenesis have also been identified. Research on the molecular biology of prostate cancer has characterized these genes into tumor suppressor genes or oncogenes. Additionally, genome-wide assay studies have identified many high-risk single-nucleotide polymorphisms recurrent throughout the prostate cancer-diagnosed genome. Castration-resistant prostate cancer is the most aggressive form of prostate cancer, and its research has elucidated many types of mutations associated with AR itself, including enhanced expression and amplification, point mutations, and alternative splicing. Understanding the molecular biology of prostate cancer has permitted more accurate identification using advanced biomarkers and therapy for aggressive forms using immunotherapy. An age-related disease, prostate cancer commands profound attention. With increasing life expectancy and the continuous pursuit of it, prostate cancer is a powerful obstacle best defeated using targeted therapies specifically designed for the unique molecular profile of the malignancy.Keywords
This publication has 116 references indexed in Scilit:
- Urinary biomarkers for prostate cancer: a reviewAsian Journal of Andrology, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyNature Genetics, 2009
- Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibilityNature Genetics, 2009
- Identification of a new prostate cancer susceptibility locus on chromosome 8q24Nature Genetics, 2009
- Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) studySocial Science & Medicine, 2009
- ETS rearrangements and prostate cancer initiationNature, 2009
- Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancerNature Genetics, 2008
- Genome-wide association study identifies novel breast cancer susceptibility lociNature, 2007
- Multiple regions within 8q24 independently affect risk for prostate cancerNature Genetics, 2007